Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Current status of therapeutic monoclonal antibodies against SARS-CoV-2.

PLoS pathogens - 1 Sept 2021

Kumar Sanjeev, Chandele Anmol, Sharma Amit

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antibodies, Neutralizing
Share to COVID-19
Share to Genetic Variation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunoglobulin Fc Fragments

Share to SARS-CoV-2

Share to Spike Glycoprotein, Coronavirus

Source

Open in PubMed Open full text

Identifiers

PMID: 34478455
DOI: 10.1371/journal.ppat.1009885
PMCID: PMC8415613

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Current status of therapeutic monoclonal antibodies against SARS-CoV-2.PMID 34478455Read ↗

In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strainsSemantic proximity Read ↗

Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2Semantic proximity Read ↗

Identification of Human Single-Domain Antibodies against SARS-CoV-2Semantic proximity Read ↗

ZRC3308 Monoclonal Antibody Cocktail Shows Protective Efficacy in Syrian Hamsters against SARS-CoV-2 Infection.Semantic proximity Read ↗

ZRC3308 monoclonal antibody cocktail shows protective efficacy in Syrian hamsters against SARS-CoV-2 infectionSemantic proximity Read ↗

Therapeutic efficacy of monoclonal antibodies and antivirals against SARS-CoV-2 Omicron BA.1 in Syrian hamstersSemantic proximity Read ↗

Conserved amino acids W423 and N424 in receptor-binding domain of SARS-CoV are potential targets for therapeutic monoclonal antibodySemantic proximity Read ↗

SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escapeSemantic proximity Read ↗

Antibody drugs targeting SARS-CoV-2: Time for a rethink?Semantic proximity Read ↗

Potent neutralizing anti-SARS-CoV-2 human antibodies cure infection with SARS-CoV-2 variants in hamster modelSemantic proximity Read ↗

Generation and characterization of a multi-functional panel of monoclonal antibodies for SARS-CoV-2 research and treatmentSemantic proximity Read ↗

Emerging mutations in the SARS-CoV-2 variants and their role in antibody escape to small molecule-based therapeutic resistance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.